Lacosamide for children with paroxysmal kinesigenic dyskinesia

Gen Furukawa, Yutaka Negishi, Tomoya Takeuchi, Naoko Ishihara, Akihisa Okumura

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Objectives: This study was performed to evaluate the efficacy and tolerability of lacosamide (LCM) for paroxysmal kinesigenic dyskinesia (PKD) in children. Methods: We retrospectively reviewed the medical charts of pediatric PKD patients (aged <16 years) treated with LCM. Data regarding demographic characteristics, proline-rich transmembrane protein 2 (PRRT2) gene variant, clinical features of PKD, dose of LCM, efficacy, and adverse events were recorded. Results: Four eligible patients (3 males, 1 female) were identified, with an age of onset ranging from 8.3 to 14.7 years. PRRT2 variant was evaluated in three children and a c.649dupC variant was identified in one child with a positive family history. Attacks were bilateral in three children and left-sided in one. Two children had a family history of PKD and one child had a family history of benign infantile epilepsy. Treatment with carbamazepine failed in two children due to drowsiness and auditory disturbance. The initial dose of LCM was 50 mg/day in three children and 100 mg/day in one. All patients were attack-free within a few days. The maintenance dose was mostly similar to the initial dose. No adverse events related to LCM were reported during follow-up. Conclusions: LCM is an effective and well-tolerated treatment for PKD in children, and low-dose treatment may be viable.

Original languageEnglish
Pages (from-to)617-620
Number of pages4
JournalBrain and Development
Issue number8
Publication statusPublished - 09-2020

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Lacosamide for children with paroxysmal kinesigenic dyskinesia'. Together they form a unique fingerprint.

Cite this